VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Petrylak on the Results of the Phase II STRIDE Study

Daniel P. Petrylak, MD
Published: Saturday, Sep 27, 2014

Daniel P. Petrylak, MD, Professor of Medicine (Medical Oncology) and of Urology, Professor and Co-Director, Signal Transduction Research Program, Yale Cancer Center, discusses results from the phase II STRIDE study.

The randomized STRIDE study evaluated concurrent versus sequential enzalutamide in combination with sipuleucel-T for the treatment of patients with metastatic castration-resistant prostate cancer.

There was no difference seen in immune parameters when comparing early and delayed enzalutamide. Further, Petrylak said, the prime-boost effect was similar in the two arms.

Anecdotally, Petrylak said, no additive or synergistic toxicities were observed. Full toxicity data will be reported later.

<<< View more from the 2014 ESMO Congress

Daniel P. Petrylak, MD, Professor of Medicine (Medical Oncology) and of Urology, Professor and Co-Director, Signal Transduction Research Program, Yale Cancer Center, discusses results from the phase II STRIDE study.

The randomized STRIDE study evaluated concurrent versus sequential enzalutamide in combination with sipuleucel-T for the treatment of patients with metastatic castration-resistant prostate cancer.

There was no difference seen in immune parameters when comparing early and delayed enzalutamide. Further, Petrylak said, the prime-boost effect was similar in the two arms.

Anecdotally, Petrylak said, no additive or synergistic toxicities were observed. Full toxicity data will be reported later.

<<< View more from the 2014 ESMO Congress




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x